Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral ...

President Donald Trump’s One Big Beautiful Bill, signed into law last week, reintroduces broader exemptions for orphan drugs ...

Arcus Biosciences (NYSE:RCUS) said on Thursday that its experimental drug candidate, quemliclustat, has received orphan drug status from the U.S. FDA. Quemliclustat is a type of medication that works ...

ADRX-0405 is uniquely being tested during its 1a/b clinical trials. ADRX-0405 is labeled as a STEAP1 ADC (primarily ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

The Senate Parliamentarian reversed course on a small provision in the One Big Beautiful Bill Act that could boost cures for ...

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

Hospitals could be on the hook for significantly higher outpatient drug prices. Because of the cuts to Medicaid, hospitals in the 340B program will see fewer Medicaid patients and may risk losing ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...